HOUSE No. 920

The Commonwealth of Massachusetts

PRESENTED BY:

Paul Brodeur

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to insurance coverage for PANDAS/PANS.

PETITION OF:

NAME:	DISTRICT/ADDRESS:	DATE ADDED:
Paul Brodeur	32nd Middlesex	1/18/2019
Jason M. Lewis	Fifth Middlesex	2/1/2019
Mark J. Cusack	5th Norfolk	2/1/2019
RoseLee Vincent	16th Suffolk	2/1/2019
Carmine Lawrence Gentile	13th Middlesex	1/28/2019
Anne M. Gobi	Worcester, Hampden, Hampshire and Middlesex	1/29/2019
Richard M. Haggerty	30th Middlesex	2/1/2019
David Henry Argosky LeBoeuf	17th Worcester	1/31/2019
Adrian C. Madaro	1st Suffolk	1/29/2019
Alice Hanlon Peisch	14th Norfolk	1/31/2019

HOUSE No. 920

By Mr. Brodeur of Melrose, a petition (accompanied by bill, House, No. 920) of Paul Brodeur and others relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. Financial Services.

The Commonwealth of Alassachusetts

In the One Hundred and Ninety-First General Court (2019-2020)

An Act relative to insurance coverage for PANDAS/PANS.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

- SECTION 1. Chapter 32A of the General Laws is hereby amended by inserting after
- 3 Section 17P. The commission shall provide to any active or retired employee of the
- 4 commonwealth who is insured under the group insurance commission, coverage for treatment of
- 5 pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and
- 6 pediatric acute-onset neuropsychiatric syndrome. Said treatment shall include, but not be limited
- 7 to, the use of Intravenous immunoglobulin (IVIG) therapy.
- 8 SECTION 2. Chapter 175 of the General Laws is hereby amended by inserting after
- 9 section 47II the following section:-

section 170 the following section:-

2

- Section 47JJ. Any policy, contract, agreement, plan or certificate of insurance issued,
- delivered or renewed within the commonwealth shall provide coverage for treatment of pediatric

autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. Said treatment shall include, but not be limited to, the use of Intravenous immunoglobulin (IVIG) therapy.

SECTION 3. Chapter 176A of the General Laws is hereby amended by inserting after section 8KK the following section:-

Section 8LL. Any contract between a subscriber and a corporation under an individual or group hospital service plan delivered, issued or renewed within the commonwealth shall provide coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. Said treatment shall include, but not be limited to, the use of Intravenous immunoglobulin (IVIG) therapy.

SECTION 4. Chapter 176B of the General Laws is hereby amended by inserting after section 4KK the following section:-

Section 4LL. Any subscription certificate under an individual or group medical service agreement delivered, issued or renewed within the commonwealth shall provide coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. Said treatment shall include, but not be limited to, the use of Intravenous immunoglobulin (IVIG) therapy.

SECTION 5. Chapter 176G of the General Laws is hereby amended by inserting after section 4CC the following section:-

Section 4DD. Any individual or group health maintenance contract shall provide coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with

- 33 streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. Said treatment
- 34 shall include, but not be limited to, the use of Intravenous immunoglobulin (IVIG) therapy.